Gries Financial LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,791 shares of the medical instruments supplier’s stock, valued at approximately $860,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Franklin Parlapiano Turner & Welch LLC raised its holdings in Becton, Dickinson and Company by 3.4% in the fourth quarter. Franklin Parlapiano Turner & Welch LLC now owns 31,890 shares of the medical instruments supplier’s stock worth $7,235,000 after purchasing an additional 1,061 shares in the last quarter. Swedbank AB raised its holdings in Becton, Dickinson and Company by 1.0% in the fourth quarter. Swedbank AB now owns 152,293 shares of the medical instruments supplier’s stock worth $34,551,000 after purchasing an additional 1,455 shares in the last quarter. Hantz Financial Services Inc. grew its stake in shares of Becton, Dickinson and Company by 7.2% in the fourth quarter. Hantz Financial Services Inc. now owns 66,904 shares of the medical instruments supplier’s stock worth $15,179,000 after acquiring an additional 4,496 shares during the last quarter. Forsta AP Fonden grew its stake in shares of Becton, Dickinson and Company by 1.6% in the fourth quarter. Forsta AP Fonden now owns 56,900 shares of the medical instruments supplier’s stock worth $12,909,000 after acquiring an additional 900 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its stake in shares of Becton, Dickinson and Company by 18.1% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 49,606 shares of the medical instruments supplier’s stock worth $11,254,000 after acquiring an additional 7,593 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.
Insider Transactions at Becton, Dickinson and Company
In related news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the transaction, the executive vice president now owns 14,217 shares in the company, valued at approximately $3,113,949.51. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 9,844 shares of company stock worth $2,210,716 over the last three months. 0.36% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on BDX
Becton, Dickinson and Company Price Performance
BDX opened at $246.85 on Thursday. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $250.91. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The business’s fifty day simple moving average is $229.10 and its 200-day simple moving average is $233.46. The company has a market capitalization of $71.59 billion, a price-to-earnings ratio of 41.56, a PEG ratio of 1.72 and a beta of 0.39.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the business posted $3.42 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.42 earnings per share for the current fiscal year.
Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its stock is undervalued.
Becton, Dickinson and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 1.69%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 70.03%.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- What Are Dividend Achievers? An Introduction
- As China Tightens Rare Earth Exports, These 3 Stocks Are in Focus
- The Significance of Brokerage Rankings in Stock Selection
- Rebuilding the Empire: Can Dollar General Rally in 2025?
- What is a buyback in stocks? A comprehensive guide for investors
- Coinbase Gains Momentum on App Store—What It Means for the Stock
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.